This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Sbi Pharmaceuticals Co., Ltd., Tokushima University. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2016
Title: Junji Chida: Innovator in Influenza Therapeutics
Introduction
Junji Chida is a notable inventor based in Tokushima, Japan. He has made significant contributions to the field of medicine, particularly in the development of therapeutic agents for viral infections. His work focuses on creating effective treatments that are safe for human use.
Latest Patents
Junji Chida holds a patent for a prophylactic and therapeutic agent for influenza virus infection. This innovative agent is designed to be effective not only before and at an early stage of infection but also during intermediate or late stages. The active ingredients include 5-aminolevulinic acid (5-ALA), its derivatives, or salts, combined with an iron compound. This agent aims to ameliorate various health issues related to influenza, such as depression in food and water consumption, body weight management, and maintaining ATP levels in the blood.
Career Highlights
Throughout his career, Junji Chida has worked with reputable organizations, including Sbi Pharmaceuticals Co., Ltd. and Tokushima University. His research and development efforts have led to advancements in the treatment of influenza, showcasing his dedication to improving public health.
Collaborations
Junji Chida has collaborated with esteemed colleagues, including Tohru Tanaka and Motowo Nakajima. These partnerships have contributed to the success of his research and the development of his patented therapeutic agent.
Conclusion
Junji Chida's innovative work in the field of influenza therapeutics highlights his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of viral infections and improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile